SBRT and hypofractionated CRT produced similar outcomes in patients with inoperable stage I NSCLC in a phase 3 trial.
A large study suggests that pediatric cancer patients are more likely to die in the hospital than at home. The data showed that 52% of patients died in the hospital, and 40% died at home. These ...
The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.